Novartis AG agreed to pay $245 million to end antitrust litigation accusing the company of trying to delay the launch of generic versions of the drug Exforge in the United States.
For the first quarter, sales decreased 1.5% year-over-year to $33.4 billion, while adjusted EPS decreased 30.8% to $1.16, down 29.9% on a constant currency basis.
In addition to an uncertain economy, another contributing factor in the layoffs was the rapid hiring Amazon conducted over the past several years to meet increased demand during the pandemic.
Albertsons has been granted a Jan. 17 review of the temporary restraining order against its previously announced $6.85-per-common-share special dividend.
The United States Court of Appeals for the Federal Circuit has granted a motion to temporarily enjoin the generic launch by Teva and Apotex of Hetlioz.